GET DAILY SIGNALSWhy Is Cellectis (CLLS) Stock Up +17.14% Today?
Key Takeaways
- Cellectis (CLLS) jumped 17.14% on Wednesday, climbing to $1.23 from a prior close of $1.05.
- The rally appears driven by bargain hunting and short covering in a heavily oversold micro-cap rather than a single company-specific catalyst.
- The stock is rebounding from deeply depressed levels after a September strategic pivot triggered a sharp selloff.
- European biopharmaceutical ADRs led the session's gainers, lending sector-level support to the move.
- Traders are watching for updates on the company's new in vivo gene-editing pipeline and its cash runway.
- For deeper context on valuation and outlook, explore Price Targets, Earnings, and Forecast pages.
- Discover AI-powered trading strategies covering this and thousands of other tickers on Trending AI Robots.
Opening Summary
Cellectis S.A. (CLLS), a Paris-based clinical-stage gene-editing biotechnology company best known for its TALEN platform and allogeneic CAR-T cell therapy research, surged 17.14% on Wednesday. Shares climbed to $1.23, up $0.18 from the prior session's closing price of $1.05, as buying momentum carried the stock sharply higher into the afternoon. The advance confirmed a two-day rebound for a name that has been under sustained pressure, and markets attributed the move largely to technical recovery and bargain hunting rather than a discrete company announcement.
A Rebound From Oversold Levels
The most straightforward explanation for Wednesday's jump is the stock's deeply depressed valuation. CLLS has lost roughly three-quarters of its value this year, trading near multi-year lows and well off its 52-week high. In mid-September, the company announced a strategic transformation toward in vivo gene editing — prioritizing preclinical candidates HEAL-101 and HEAL-201 — while discontinuing development of its CAR-T cell therapy programs lasme-cel and eti-cel. That pipeline overhaul triggered a sharp repricing, analyst downgrades, and, in some cases, law-firm inquiries. With the stock trading near its 52-week low of $0.88, the recent sessions have invited dip buyers looking to position for a potential recovery in sentiment.
Short Covering and Technical Momentum
Heavily shorted, low-float biotechnology names are prone to sharp, abrupt rallies when sentiment stabilizes. With CLLS trading near depressed levels, even a modest influx of buyers can force short sellers to cover positions, amplifying upside moves. The stock also gained more than 8% in the prior session, suggesting a building short-term momentum that carried into Wednesday's 17% surge. This pattern — a fast, catalyst-light advance on elevated trading activity — is characteristic of short covering and momentum-driven re-entry rather than a fundamental re-rating.
Sector Sympathy and Broader Market Context
The move also aligned with broader strength in European biotechnology shares trading as American depositary receipts in the United States. CLLS was among the leading gainers in the group, advancing alongside peers such as DBVT, reflecting a favorable tone for biopharmaceutical ADRs during the session. While the stock's outsized percentage move reflects its low share price and micro-cap status, sector-level risk appetite provided a supportive backdrop for the rebound.
Market Context and Trading Activity
Trading activity picked up notably as the rally accelerated, with volume in recent sessions exceeding the stock's typical turnover for this size of company. The move pushed shares well above the prior session's close and back toward levels last seen earlier in the month, though the stock remains far below its longer-term moving averages and its 52-week high of approximately $5.45. Broader equity benchmarks were relatively subdued during the session, indicating that Wednesday's advance was stock- and sector-specific rather than a reflection of a broad market rally.
What Comes Next for CLLS
Looking ahead, investors will focus on how Cellectis executes its newly refocused in vivo gene-editing strategy and communicates progress on its preclinical candidates. Key considerations include the company's cash runway, which management has previously indicated extends into 2027, as well as any updates on its partnerships with AstraZeneca, Servier, and Allogene. Analysts remain divided, with some maintaining constructive longer-term views based on the company's gene-editing platform while others point to the loss of near-term clinical catalysts following the discontinuation of the CAR-T programs. As a low-priced, high-beta stock, CLLS is likely to remain volatile, with continued sensitivity to pipeline news, funding developments, and shifts in biotech sentiment.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots from a library of hundreds covering thousands of tickers. Only the strongest performers under current market conditions are featured, with each bot varying by strategy, timeframe, performance metrics, and the symbols it trades. Investors and traders seeking data-driven approaches to navigate fast-moving stocks like CLLS may find value in exploring the platform's featured strategies.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CLLS in upward trend: price may jump up because it broke its lower Bollinger Band on October 12, 2026
CLLS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 32 of 36 cases where CLLS's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CLLS's RSI Indicator exited the oversold zone, 25 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 47 of 60 cases where CLLS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
The Moving Average Convergence Divergence (MACD) for CLLS just turned positive on October 05, 2026. Looking at past instances where CLLS's MACD turned positive, the stock continued to rise in 37 of 45 cases over the following month. The odds of a continued upward trend are 82%.
Following a +1.19% 3-day Advance, the price is estimated to grow further. Considering data from situations where CLLS advanced for three days, in 170 of 215 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CLLS as a result. In 77 of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLLS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for CLLS entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 61 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.575) is normal, around the industry mean (2.974). P/E Ratio (-1.641) is within average values for comparable stocks, (-0.899). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.903) among similar stocks. P/S Ratio (2.441) is also within normal values, averaging (439.237).
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 94 (best 1 - 100 worst), indicating slightly worse than average price growth. CLLS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLLS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a genome engineering company of pre-engineered products for pharmaceutical industry, cell therapies, seed companies, and laboratory researchers
Industry Biotechnology
Advertisement